Meneldor

Tagworks Pharmaceuticals is a privately held biotech company based in the Netherlands, established in 2011 as a spin-out from Philips Healthcare. The company focuses on developing innovative in vivo chemistry to enhance the effectiveness of cancer therapies and to facilitate novel companion diagnostics. Operating from the Radboud University Medical Center in Nijmegen, Tagworks specializes in antibody-based imaging and therapy technologies. Its proprietary approach allows for the selective chemical manipulation of tagged antibodies in vivo, which improves the efficacy of established methods like radioimmuno-imaging and antibody-drug conjugates. This technology enables medical professionals to conduct imaging with significantly reduced radiation exposure for patients.

Hemispherian is a biotechnology firm focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The company specializes in creating personalized cancer therapies and is engaged in the development of a novel class of small-molecule drugs. By concentrating on areas of unmet medical need, Hemispherian aims to provide physicians with access to advanced therapeutic options that could improve patient outcomes in challenging cancer cases.

Hemispherian is a biotechnology firm focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The company specializes in creating personalized cancer therapies and is engaged in the development of a novel class of small-molecule drugs. By concentrating on areas of unmet medical need, Hemispherian aims to provide physicians with access to advanced therapeutic options that could improve patient outcomes in challenging cancer cases.

Atriva Therapeutics GmbH is a biopharmaceutical company based in Tübingen, Germany, that specializes in developing antiviral therapies for respiratory viral infections, particularly seasonal and pandemic influenza. Founded in 2015, the company is focused on its lead product, ATR-002, a Mitogen-activated protein kinase inhibitor designed to target host cells and inhibit viral replication. Atriva Therapeutics has completed the preclinical development of ATR-002 and is seeking scientific advice from European regulatory authorities to inform its planned Phase I study in healthy volunteers. The company aims to create safe and effective treatments for severe diseases caused by RNA viruses, addressing a significant unmet medical need and the associated healthcare costs globally.

Atriva Therapeutics GmbH is a biopharmaceutical company based in Tübingen, Germany, that specializes in developing antiviral therapies for respiratory viral infections, particularly seasonal and pandemic influenza. Founded in 2015, the company is focused on its lead product, ATR-002, a Mitogen-activated protein kinase inhibitor designed to target host cells and inhibit viral replication. Atriva Therapeutics has completed the preclinical development of ATR-002 and is seeking scientific advice from European regulatory authorities to inform its planned Phase I study in healthy volunteers. The company aims to create safe and effective treatments for severe diseases caused by RNA viruses, addressing a significant unmet medical need and the associated healthcare costs globally.

Aptamer Group Limited is a biotechnology company based in York, United Kingdom, specializing in the development of aptamer technology. Founded in 2008, the company creates nucleic acid aptamers, which are short DNA or RNA sequences designed to bind with high affinity and specificity to a variety of targets, serving as an alternative to traditional antibodies. Aptamer Group offers tailored solutions for research and development, biomarker discovery, diagnostics, and therapeutic applications. Its proprietary Optimer technology enables the rapid selection and optimization of aptamers for diverse targets such as peptides, proteins, cells, and small molecules. The company's services include Optimer development, diagnostic assay creation, and therapeutic applications, with a focus on delivering high-quality, cost-effective solutions across the life sciences sector. Aptamer Group's innovative approach allows for faster development timelines compared to monoclonal antibodies, fulfilling a wide range of applications, including imaging, quantification, rapid diagnostics, and purification.